Experiment DesignFreemium🔗 source linked

IBM RXN for Chemistry

Web-based AI platform for retrosynthesis planning and forward reaction prediction — suggests multi-step synthetic routes to target molecules and predicts reaction outcomes from reagents.

Last verified: July 2026

What it does

IBM RXN for Chemistry is a web platform that applies AI to two core synthesis tasks: retrosynthesis (working backward from a target molecule to identify feasible synthetic routes) and forward reaction prediction (predicting the product of a reaction given starting materials and reagents). You enter a molecule in SMILES format or draw it using the built-in editor, and the tool proposes routes and reaction conditions ranked by predicted feasibility.

The platform was recently updated with integration of Thieme’s Science of Synthesis database — a curated expert-authored collection covering reaction classes underrepresented in the patent literature that most models train on. IBM Research reports approximately 9× improvement in retrosynthesis prediction accuracy and ~3× improvement in forward prediction following this integration.

Best for

Chemists planning synthetic routes to target molecules, particularly for drug discovery, natural product synthesis, or materials chemistry. Also useful as a first-pass sanity check when evaluating whether a proposed molecule is synthetically feasible before running a de novo design campaign.

Pricing

Freemium. A free tier provides basic retrosynthesis and forward prediction. The full multi-step synthesis planning feature (planning routes up to 40+ steps) and higher-throughput access require a paid account. Institutional licenses available.

Strengths

  • End-to-end synthesis planning from a single target molecule — not just one retrosynthetic step but multi-step route proposals
  • Forward prediction validates proposed routes: given a reaction you’re planning, it predicts the likely product and flags low-confidence predictions
  • Web-based with a molecule drawing editor — no Python required; accessible to researchers without ML infrastructure
  • Science of Synthesis integration substantially improved accuracy, especially for reaction classes outside the patent literature mainstream
  • Routes can be exported for use in electronic lab notebooks

Limitations

  • Training data is biased toward well-documented reaction classes in patents and literature — truly novel or exotic reaction types remain less reliable
  • Stereochemistry handling (which face of a molecule a reagent attacks, enantioselectivity) is less reliable than connectivity prediction
  • Route proposals are ranked by model confidence, not by practical ease, cost of starting materials, or lab availability — always filter suggested routes through your practical constraints
  • A proposed route that the model rates highly still needs expert evaluation and experimental validation before trusting it

How it compares

vs. Key difference
Molecule.one Molecule.one focuses more heavily on commercial availability of intermediates and route cost; IBM RXN is broader in reaction type coverage
REINVENT 4 REINVENT 4 is a de novo molecule generator, not a route planner — they address different parts of the drug discovery workflow
Chemprop Chemprop predicts molecular properties (activity, solubility); IBM RXN predicts reactions and routes — complementary, not competing
Manual retrosynthesis AI retrosynthesis is faster for generating candidate routes; expert chemist judgment is still needed to evaluate and select among them